Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation limited to the colon, progressing proximally from the rectum, resulting from dysregulated immune responses to the gut microbiome in genetically susceptible individuals. The disease manifests with bloody diarrhea, urgency, tenesmus, and carries a 2-8% lifetime risk of colorectal cancer. UC represents a fundamental failure of resolution mechanisms rather than excessive initial inflammation, with defective Specialized pro-resolving mediators (SPMs) production and impaired efferocytosis.
Imagine a municipal waste management system in a coastal city where the garbage collection crews have forgotten how to finish their shifts. Every day, sanitation workers (neutrophils) arrive at the waterfront district (colon mucosa) and start collecting trash (microbial antigens). They pile it up efficiently, but then they just... stand there. They never take the garbage to the landfill, never clock out, never go home. More crews arrive the next day, and the next, adding to the chaos.
The problem isn't that there's too much garbage initiallyβit's that nobody knows how to clean up and leave. The shift supervisors (resolvins, protectins, maresins) who normally blow the whistle and say "job's done, pack it up" are either absent or speaking a language the workers no longer understand. Meanwhile, the waterfront barrier wall (gut barrier) develops cracks from the constant activity, allowing seawater (luminal contents) to seep into the streets behind it. Certain troublemaker bacteria (adherent-invasive E. coli) notice these cracks and set up camp in the wall itself. The factories that used to produce fuel for the city (butyrate-producing bacteria) have shut down, so there's no energy to repair the wall. What started as normal maintenance has become a permanent state of unresolved chaos, and the constant presence of workers eventually damages the waterfront infrastructure so severely that precancerous changes begin to develop in the pavement itself.
UC pathogenesis involves multiple interconnected failures:
Barrier Dysfunction Cascade:
Immune Dysregulation:
graph TD
A[Barrier Breach] --> B["PAMPs + DAMPs"]
B --> C[Dendritic Cells]
C --> D[Th2/Th17 Polarization]
D --> E[IL-4, IL-5, IL-13]
D --> F[IL-17A, IL-17F, IL-23]
E --> G[Eosinophil Recruitment]
F --> H[Neutrophil Recruitment]
H --> I[Tissue Damage]
I --> J[More DAMPs]
J --> B
K[Defective Treg Function] --> L[Loss of Tolerance]
L --> D
M[SPM Deficiency] --> N[Impaired Resolution]
N --> O[Chronic Inflammation]
I --> O
- Dendritic cells present microbial antigens β preferential Th2/Th17 activation (genetic predisposition via HLA alleles)
- Th2 response: IL-4, IL-5, IL-13 β eosinophil recruitment, IgE production, epithelial barrier damage
- Th17 response: IL-17A, IL-17F β neutrophil chemotaxis via CXCL1, IL-8
- IL-23 (from activated macrophages) β sustains Th17 population β chronic IL-17A secretion
- Treg cells dysfunction: reduced IL-10, TGF-beta production β loss of mucosal tolerance
- FOXP3 expression defects in Tregs β inability to suppress effector T cells
Resolution Failure (Central to UC Pathology):
Dysbiosis Pattern:
Chronic Inflammatory Carcinogenesis:
- Persistent IL-6 β STAT3 activation β c-Myc, Bcl-xL upregulation β anti-apoptotic effect
- TNF-Ξ± β NF-ΞΊB β COX-2 β PGE2 β promotes dysplasia
- Chronic oxidative stress (ROS from neutrophils) β DNA damage β p53 mutations
- Nitric Oxide + superoxide β peroxynitrite β nitrosative DNA damage
- Risk increases 0.5-1% per year after 8-10 years of disease, 18% at 30 years
Resolution-Centric Disease Model:
UC is the archetypal resolution failure disease in cPNI. Unlike acute inflammation that transitions through initiation β amplification β resolution, UC represents arrested development at the amplification phase. Patients are literally unable to complete inflammatory programsβtheir immune systems start fights but have no exit strategy. This reframes treatment: instead of merely suppressing inflammation (standard immunosuppressants), cPNI interventions target resolution pathway restoration.
Clinical Phenotypes:
- Proctitis (30-40% of cases): inflammation limited to rectum, best prognosis
- Left-sided colitis (40%): extends to splenic flexure
- Extensive/pancolitis (20-30%): proximal to splenic flexure, highest cancer risk
- Disease extent correlates with Calprotectin levels (>250 ΞΌg/g indicates active inflammation)
Selfish Systems Framework:
The selfish immune system prioritizes pathogen elimination over tissue preservation. In UC, commensal bacteria are misidentified as threats due to barrier dysfunction, triggering perpetual immune activation. The selfish brain responds to colonic inflammation via vagus nerve afferents, creating sickness behaviour, fatigue, and depression (40% of UC patients meet criteria for major depression). The gut's desperate signals for resources (amino acids for repair, energy for barrier maintenance) compete with brain glucose demands, creating the characteristic UC fatigue.
Psychoneuroimmune Factors:
Intervention Framework:
- SPM Restoration: EPA/DHA supplementation (2-4g daily), aspirin-triggered SPMs (low-dose aspirin 81mg enhances resolvin production)
- Microbiome Repair: Faecalibacterium prausnitzii supplementation, resistant starch (20-30g/day) to boost butyrate producers
- Barrier Support: L-glutamine (15-30g/day), zinc carnosine (150mg zinc/day), vitamin D (target 50-80 ng/mL)
- Resolution Nutrients: Specialized pro-resolving mediators (SPMs) precursors, Curcumin (activates ALX-FPR2 receptor), Resveratrol (enhances 15-LOX)
- Stress Axis Regulation: Vagus nerve stimulation, meditation (reduces IL-6, CRP), Rhodiola rosea (adaptogenic support)
- Efferocytosis Enhancement: Vitamin E (400 IU), Selenium (200ΞΌg) to support macrophage clearance function
Monitoring:
- Calprotectin <50 ΞΌg/g indicates remission
- CRP less sensitive than calprotectin in UC (elevated in only 50% of active disease)
- Endoscopic Mayo score: 0-3 scale (0 = normal, 3 = severe with spontaneous bleeding)
- Histologic remission (absence of basal plasmacytosis, crypt distortion) predicts sustained remission better than clinical or endoscopic markers
- Inflammation is continuous from rectum proximally, unlike Crohn's disease (skip lesions)
- Peak incidence: 20-40 years, secondary peak 50-70 years
- Genetic component: 15% have first-degree relative with IBD; concordance in twins 10-15% (vs 50% in Crohn's)
- Calprotectin >250 ΞΌg/g indicates active inflammation with 93% sensitivity
- Butyrate concentrations in UC patients typically 20-40% of healthy controls
- Faecalibacterium prausnitzii abundance inversely correlates with disease severity (r = -0.67)
- Colorectal cancer risk: 2% at 10 years, 8% at 20 years, 18% at 30 years of disease
- RvD1 levels in UC colonic tissue are 60-80% lower than healthy mucosa
- IL-6 >10 pg/mL in serum correlates with disease activity
- 40% of UC patients have extraintestinal manifestations: primary sclerosing cholangitis (5%), ankylosing spondylitis (5%), erythema nodosum, episcleritis
- Smoking paradoxically protective in UC (unlike Crohn's)βlikely via nicotine β cholinergic anti-inflammatory pathway activation
- Appendix removal before age 20 reduces UC risk by 69% (appendix as reservoir for pathogenic bacteria)
- inflammatory bowel disease β disease category; UC represents the resolution-failure phenotype
- Crohn's disease β transmural IBD counterpart; shares dysbiosis but distinct immune signature (Th1/Th17 vs UC's Th2/Th17)
- Specialized pro-resolving mediators (SPMs) β deficiency central to UC pathology; therapeutic restoration targets
- Resolvins β RvD1, RvD2, RvE1 reduced 60-80% in UC tissue; supplementation reduces disease activity
- Protectins β neuroprotectin D1 deficient in UC; promotes resolution and mucosal healing
- Maresins β MaR1 levels inversely correlate with Mayo score; enhances efferocytosis
- Lipoxins β aspirin-triggered lipoxins (ATL) via ALX-FPR2 provide anti-inflammatory signals
- barrier dysfunction β initiating event allowing microbial translocation and immune activation
- gut barrier β epithelial tight junction loss and mucus defects enable UC pathogenesis
- dysbiosis β hallmark feature; loss of diversity and butyrate producers drives inflammation
- Butyrate β colonocyte fuel depleted in UC; supplementation via resistant starch aids remission
- Faecalibacterium prausnitzii β keystone species lost in UC; oral supplementation shows promise
- Treg cells β deficient in UC (reduced FOXP3+ cells in lamina propria); tolerance restoration essential
- chronic inflammation β sustained immune activation from resolution failure creates cancer risk
- colorectal cancer β UC's most feared complication; risk proportional to extent and duration
- Efferocytosis β impaired clearance of apoptotic neutrophils perpetuates inflammation
- lipid mediator class switching β failure to switch from leukotrienes to SPMs sustains UC
- IL-6 β elevated in active UC; crosses blood-brain barrier contributing to fatigue and depression
- TNF-Ξ± β pro-inflammatory cytokine; anti-TNF biologics (infliximab) effective in moderate-severe UC
- tight junctions β occludin and ZO-1 disruption allows paracellular permeability
- gut microbiome β compositional changes precede clinical relapse by weeks; microbiome profiling predicts flares
- PAMPs β bacterial LPS, flagellin trigger TLR4/TLR5 when barrier compromised
- stress β psychological stress triggers mast cell degranulation via CRH, increasing permeability
- vagus nerve β afferent signals from inflamed colon create sickness behaviour and HPA axis activation
- sickness behaviour β fatigue, anhedonia, social withdrawal in UC mediated by IL-1Ξ², IL-6 actions on brain
- mucus layer β MUC2 defects allow bacterial adherence to epithelium in UC
- oxidative stress β neutrophil ROS production creates DNA damage driving dysplasia-carcinoma sequence
- Depression β 40% comorbidity in UC; bidirectional via cytokine effects on hippocampus and tryptophan metabolism
- Calprotectin β neutrophil-derived protein; fecal levels correlate with endoscopic disease activity